AdvaMed To Seek Legislative Fix To Ease New Tech Add-On Payment Criteria
This article was originally published in The Gray Sheet
Executive Summary
CMS' discovery that Stryker Biotech (OP-1) has offered a comparable product to Medtronic's InFuse bone graft for tibia fractures since 2001 led the agency to reject the latter firm's new technology add-on application
You may also be interested in...
Medtronic Seeks InFuse Add-on, Proposes Clearer Definition Of “Similarity”
CMS should reconsider granting new technology add-on payment for Medtronic's InFuse bone graft for tibia fractures by using a clearer definition of "substantial improvement," according to the company
Medtronic Seeks InFuse Add-on, Proposes Clearer Definition Of “Similarity”
CMS should reconsider granting new technology add-on payment for Medtronic's InFuse bone graft for tibia fractures by using a clearer definition of "substantial improvement," according to the company
New Tech Add-On Payments: Plan Early, Meet Often With CMS – Kuhn, Farkas
Early and frequent communication with CMS will enhance new technology add-on payment applicants' prospects for success, according to Center for Medicare Management Director Herb Kuhn